4. #StarterNET: Ph 3, unressctable/recurrent non functional G1/2 GEP NET, 1L Lanreotide + everolimus vs everolimus - Improved ORR (23% vs 8.3%) - Improved PFS in all subsets w/ combo - No OS difference at 1 year - Great summary for CRC NETs by @UGrewalMD 5/8

OncBrothers's tweet image. 4. #StarterNET: Ph 3, unressctable/recurrent non functional G1/2 GEP NET, 1L Lanreotide + everolimus vs everolimus 

- Improved ORR (23% vs 8.3%)
- Improved PFS in all subsets w/ combo
- No OS difference at 1 year
- Great summary for CRC NETs by @UGrewalMD 

5/8
OncBrothers's tweet image. 4. #StarterNET: Ph 3, unressctable/recurrent non functional G1/2 GEP NET, 1L Lanreotide + everolimus vs everolimus 

- Improved ORR (23% vs 8.3%)
- Improved PFS in all subsets w/ combo
- No OS difference at 1 year
- Great summary for CRC NETs by @UGrewalMD 

5/8
OncBrothers's tweet image. 4. #StarterNET: Ph 3, unressctable/recurrent non functional G1/2 GEP NET, 1L Lanreotide + everolimus vs everolimus 

- Improved ORR (23% vs 8.3%)
- Improved PFS in all subsets w/ combo
- No OS difference at 1 year
- Great summary for CRC NETs by @UGrewalMD 

5/8
OncBrothers's tweet image. 4. #StarterNET: Ph 3, unressctable/recurrent non functional G1/2 GEP NET, 1L Lanreotide + everolimus vs everolimus 

- Improved ORR (23% vs 8.3%)
- Improved PFS in all subsets w/ combo
- No OS difference at 1 year
- Great summary for CRC NETs by @UGrewalMD 

5/8

🚨 Masterclass on management of colorectal neuroendocrine tumors (well-differentiated) by Dr Jen Chan at #GI25 🌎 rising incidence, primarily driven by rectal NETs 📌 most CR NETs are non functional ‼️Grade, size and depth of invasion are some high risk features pre-resection.…

UGrewalMD's tweet image. 🚨 Masterclass on management of colorectal neuroendocrine tumors (well-differentiated) by Dr Jen Chan at #GI25 

🌎 rising incidence, primarily driven by rectal NETs
📌 most CR NETs are non functional
‼️Grade, size and depth of invasion are some high risk features pre-resection.…


The new domain name starternet .com has been listed for sale at perfectdomain.com , buy it before its gone! click here: perfectdomain.com/domain/starter… #Starter #Tern #Starternet


4. #StarterNET: Ph 3, unressctable/recurrent non functional G1/2 GEP NET, 1L Lanreotide + everolimus vs everolimus - Improved ORR (23% vs 8.3%) - Improved PFS in all subsets w/ combo - No OS difference at 1 year - Great summary for CRC NETs by @UGrewalMD 5/8

OncBrothers's tweet image. 4. #StarterNET: Ph 3, unressctable/recurrent non functional G1/2 GEP NET, 1L Lanreotide + everolimus vs everolimus 

- Improved ORR (23% vs 8.3%)
- Improved PFS in all subsets w/ combo
- No OS difference at 1 year
- Great summary for CRC NETs by @UGrewalMD 

5/8
OncBrothers's tweet image. 4. #StarterNET: Ph 3, unressctable/recurrent non functional G1/2 GEP NET, 1L Lanreotide + everolimus vs everolimus 

- Improved ORR (23% vs 8.3%)
- Improved PFS in all subsets w/ combo
- No OS difference at 1 year
- Great summary for CRC NETs by @UGrewalMD 

5/8
OncBrothers's tweet image. 4. #StarterNET: Ph 3, unressctable/recurrent non functional G1/2 GEP NET, 1L Lanreotide + everolimus vs everolimus 

- Improved ORR (23% vs 8.3%)
- Improved PFS in all subsets w/ combo
- No OS difference at 1 year
- Great summary for CRC NETs by @UGrewalMD 

5/8
OncBrothers's tweet image. 4. #StarterNET: Ph 3, unressctable/recurrent non functional G1/2 GEP NET, 1L Lanreotide + everolimus vs everolimus 

- Improved ORR (23% vs 8.3%)
- Improved PFS in all subsets w/ combo
- No OS difference at 1 year
- Great summary for CRC NETs by @UGrewalMD 

5/8

🚨 Masterclass on management of colorectal neuroendocrine tumors (well-differentiated) by Dr Jen Chan at #GI25 🌎 rising incidence, primarily driven by rectal NETs 📌 most CR NETs are non functional ‼️Grade, size and depth of invasion are some high risk features pre-resection.…

UGrewalMD's tweet image. 🚨 Masterclass on management of colorectal neuroendocrine tumors (well-differentiated) by Dr Jen Chan at #GI25 

🌎 rising incidence, primarily driven by rectal NETs
📌 most CR NETs are non functional
‼️Grade, size and depth of invasion are some high risk features pre-resection.…


The new domain name starternet .com has been listed for sale at perfectdomain.com , buy it before its gone! click here: perfectdomain.com/domain/starter… #Starter #Tern #Starternet


4. #StarterNET: Ph 3, unressctable/recurrent non functional G1/2 GEP NET, 1L Lanreotide + everolimus vs everolimus - Improved ORR (23% vs 8.3%) - Improved PFS in all subsets w/ combo - No OS difference at 1 year - Great summary for CRC NETs by @UGrewalMD 5/8

OncBrothers's tweet image. 4. #StarterNET: Ph 3, unressctable/recurrent non functional G1/2 GEP NET, 1L Lanreotide + everolimus vs everolimus 

- Improved ORR (23% vs 8.3%)
- Improved PFS in all subsets w/ combo
- No OS difference at 1 year
- Great summary for CRC NETs by @UGrewalMD 

5/8
OncBrothers's tweet image. 4. #StarterNET: Ph 3, unressctable/recurrent non functional G1/2 GEP NET, 1L Lanreotide + everolimus vs everolimus 

- Improved ORR (23% vs 8.3%)
- Improved PFS in all subsets w/ combo
- No OS difference at 1 year
- Great summary for CRC NETs by @UGrewalMD 

5/8
OncBrothers's tweet image. 4. #StarterNET: Ph 3, unressctable/recurrent non functional G1/2 GEP NET, 1L Lanreotide + everolimus vs everolimus 

- Improved ORR (23% vs 8.3%)
- Improved PFS in all subsets w/ combo
- No OS difference at 1 year
- Great summary for CRC NETs by @UGrewalMD 

5/8
OncBrothers's tweet image. 4. #StarterNET: Ph 3, unressctable/recurrent non functional G1/2 GEP NET, 1L Lanreotide + everolimus vs everolimus 

- Improved ORR (23% vs 8.3%)
- Improved PFS in all subsets w/ combo
- No OS difference at 1 year
- Great summary for CRC NETs by @UGrewalMD 

5/8

🚨 Masterclass on management of colorectal neuroendocrine tumors (well-differentiated) by Dr Jen Chan at #GI25 🌎 rising incidence, primarily driven by rectal NETs 📌 most CR NETs are non functional ‼️Grade, size and depth of invasion are some high risk features pre-resection.…

UGrewalMD's tweet image. 🚨 Masterclass on management of colorectal neuroendocrine tumors (well-differentiated) by Dr Jen Chan at #GI25 

🌎 rising incidence, primarily driven by rectal NETs
📌 most CR NETs are non functional
‼️Grade, size and depth of invasion are some high risk features pre-resection.…


Loading...

Something went wrong.


Something went wrong.


United States Trends